• (S)-Mephenytoin in CYP2C19 Substrate Assays: Protocols & Pit

  2026-06-17

  (S)-Mephenytoin stands as the gold-standard CYP2C19 substrate, now empowering human-relevant pharmacokinetic studies using hiPSC-derived intestinal organoids. This article details practical workflows, troubleshooting strategies, and the latest comparative advantages for leveraging APExBIO’s high-purity (S)-Mephenytoin in advanced oxidative drug metabolism research.

• Luminescent ATP Detection Assay Kit: Precision in Cellular M

  2026-06-17

  Unlock high-sensitivity cellular ATP quantification using APExBIO’s Luminescent ATP Detection Assay Kit. Discover protocol enhancements and troubleshooting strategies that empower translational research in cancer metabolism and beyond.

• Oleic Acid (C18:1(9Z)): Bridging Mechanism and Translation

  2026-06-16

  This thought-leadership article explores the mechanistic and translational significance of Oleic Acid (C18:1(9Z)) in lipid metabolism, inflammation, and cancer biology. Integrating recent evidence from hepatic ischemia-reperfusion injury models, it offers protocol best practices, strategic insights, and highlights APExBIO's high-quality Oleic Acid (C4977) as an indispensable research tool. The article uniquely escalates the conversation beyond standard product pages by connecting foundational science with actionable guidance for translational researchers.

• C34 TLR4 Inhibitor: Optimizing Inflammatory Pathway Research

  2026-06-16

  C34 offers precise, selective TLR4 inhibition, enabling researchers to dissect inflammatory signaling in macrophages and enterocytes with minimal off-target effects. Its proven efficacy in both in vitro and in vivo models—backed by quantitative data—makes it a standout tool for studies in necrotizing enterocolitis and neuroinflammation.

• EZH2 Inhibition Reactivates FMR1 in Fragile X Syndrome Neuro

  2026-06-15

  This study identifies EZH2 as a key epigenetic silencer of FMR1 in Fragile X syndrome and demonstrates that EZH2 inhibition can reactivate FMR1 expression and normalize neuronal function in patient-derived cells. These findings expand the therapeutic scope of EZH2 inhibitors beyond oncology, highlighting their mechanistic potential for neurodevelopmental disorders.

• Structural Insights Into MK 0893 Binding to Glucagon Recepto

  2026-06-15

  This study elucidates the 2.5 Å crystal structure of the human glucagon receptor in complex with MK 0893, identifying a previously unknown, extra-helical allosteric binding site. The findings provide a foundation for structure-based drug design targeting GCGR and deepen mechanistic understanding of antagonist-mediated receptor inhibition in type 2 diabetes research.

• Distinct Apoptotic Pathways in BMECs Triggered by Candida kr

  2026-06-14

  This study demonstrates that yeast and hypha forms of Candida krusei induce apoptosis in bovine mammary epithelial cells (BMECs) via fundamentally different signaling pathways. By dissecting the involvement of mitochondrial and death receptor mechanisms, as well as the JNK/ERK and Toll-like receptor pathways, the research provides a foundation for targeted intervention strategies in mycotic mastitis.

• Baicalin for KEAP1-NRF2/HO-1 Pathway Modulation in Research

  2026-06-13

  Baicalin offers a powerful, reproducible tool for modulating KEAP1-NRF2/HO-1 and TGF-β1/p-Smad3 pathways, enabling cutting-edge research in neuroplasticity and oncology. Learn how APExBIO's ultra-pure Baicalin streamlines complex experimental workflows with actionable protocol parameters and real-world troubleshooting advice.

• Structural Basis of Fatty Acid Odor Detection by Class II OR

  2026-06-12

  Han et al. provide mechanistic insight into how class II olfactory receptors (ORs), specifically Olfr110, recognize hydrophobic unsaturated fatty acid metabolites using cryo-EM. Their findings reveal a dual-pocket architecture and unconventional activation pathway, informing future research on odorant detection and receptor-targeted drug design.

• Applied Use of (-)-Blebbistatin in Non-Muscle Myosin II Inhi

  2026-06-12

  (-)-Blebbistatin delivers precise, reversible control of non-muscle myosin II, enabling reproducible dissection of actin-myosin interactions in complex cell systems. This guide presents actionable protocols, real-world troubleshooting, and workflow innovations that maximize its performance for cytoskeletal mechanics and cardiac research.

• Optimizing Protein Stability for Dual OXPHOS Targeting in Ca

  2026-06-11

  This thought-leadership article explores the mechanistic and translational imperatives for precise protease inhibition in advanced cancer research, spotlighting the synergy between LRPPRC inhibition and Dasatinib in dual-genome OXPHOS disruption. It highlights the critical role of EDTA-free protease inhibitor cocktails—specifically APExBIO's DMSO-formulated solution—in ensuring data fidelity during complex protein extraction workflows. The article bridges experimental evidence, protocol optimization, and strategic guidance for translational researchers, while contextualizing its contribution within and beyond existing literature.

• Cy3 TSA Fluorescence System Kit for Quantitative Lipogenesis

  2026-06-11

  Explore how the Cy3 TSA Fluorescence System Kit enables ultra-sensitive, quantitative mapping of de novo lipogenesis pathways in cancer research. This in-depth analysis bridges advanced signal amplification with transcriptional regulation insights, providing new protocols and practical guidance.

• 25-Hydroxycholesterol Drives Lysosomal AMPK Activation in TA

  2026-06-10

  Xiao et al. (2024) elucidate how lysosomal 25-hydroxycholesterol (25HC) activates AMPKα via the GPR155-mTORC1 complex in tumor-associated macrophages (TAMs), promoting STAT6-dependent immunosuppressive programming. Targeting the CH25H-25HC-AMPK axis reprograms macrophage metabolism and enhances antitumor immunity, revealing new intervention points for improving immunotherapy.

• 2-Deoxy-D-glucose: Applied Glycolysis Inhibition in Cancer R

  2026-06-10

  2-Deoxy-D-glucose (2-DG) from APExBIO enables precise metabolic modulation in cancer, immunology, and virology workflows. This guide details advanced use-cases, stepwise experimental protocols, and troubleshooting strategies for maximizing 2-DG's impact as a glycolysis inhibitor and metabolic oxidative stress inducer.

• Sorafenib (BAY-43-9006) in Cancer Biology: Applied Workflows

  2026-06-09

  Sorafenib (BAY-43-9006) stands out as a robust cancer biology research tool, enabling precise dissection of antiangiogenic and antiproliferative mechanisms in tumor models. This article delivers workflow-level guidance, protocol optimization, and troubleshooting strategies to maximize the impact of Sorafenib in both in vitro and in vivo experimental designs.

15615 records 1/1041 page Next 12345 下5页 Last page